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Abstract
Central nervous system diseases represent a huge world of burden of human suffering 
with negative economic results. Most therapeutic compounds cannot attain the brain 
because of the blood-brain barrier and its expression of efflux transporters. Among them, 
the P-glycoprotein plays a significant role leading to failure of various clinical treat-
ments. A non-invasive strategy to circumvent the blood-brain barrier and P-glycoprotein 
emphasizes on the encapsulation and therefore masking of therapeutic compounds in 
drug delivery systems. Up to now, liposomes are the most widely studied drug delivery 
systems due to their biocompatibility, biodegradability, and less toxicity. The incorpora-
tion of polyethylene glycol-lipid derivatives within the bilayer of conventional liposomes 
significantly prolongs liposomal cargo half-life by steric stabilization. Interestingly, an 
increased brain accumulation of liposomal cargo is achieved by coupling targeting moi-
eties on liposomes surface. These targeting moieties such as peptides or monoclonal 
antibodies recognize the biochemical transport systems at the blood-brain barrier and 
mediate the transport of liposomes and their cargo across this barrier. Moreover, stim-
uli-sensitive liposomes are programmed for cargo release when exposed to a particular 
microenvironment. Hence, this chapter highlights the potential liposomal applications 
for delivery of therapeutic compounds as well as diagnostic tools or both, in major central 
nervous system diseases.
Keywords: central nervous system diseases, blood-brain barrier, P-glycoprotein, liposomes, 
passive targeting, active targeting, stimuli strategies
1. Introduction
Most neurological disorders compromise the central nervous system (CNS) and its main 
organ, the brain. These disorders include stroke, brain cancer, Alzheimer’s disease, Parkinson’s 
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disease, epilepsy, multiple sclerosis, neuroinfections, and traumatic disorders of the nervous 
system, among others (http://www.who.int/en/). Because millions of people worldwide are 
affected by CNS disorders, they constitute 6.3% of the global burden of disease. In other words, 
CNS diseases are a huge world of burden of human suffering with negative economic results 
[1]. Most of the therapeutic molecules cannot attain the brain because of the presence of the 
blood-brain barrier (BBB), which separates the bloodstream from the cerebral parenchyma [2]. 
This barrier is mainly composed by endothelial cells, which are linked by tight junctions [3]. 
The BBB also contains a basal membrane, pericytes, and astrocytes [3]. More important is the 
presence of efflux transporters that perform active back-transport of the therapeutic molecules 
to the blood lumen. P-glycoprotein (P-gp) is the most important efflux transporter associated 
to the failure of various therapies to treat CNS diseases [4]. Advances in nanomedicine have 
created a non-invasive strategy for the management of CNS diseases [5]. This strategy empha-
sizes on the encapsulation of therapeutic compounds, which are mainly P-gp substrates, in 
drug delivery systems, also called nanocarriers, such as liposomes, lipid nanocapsules, poly-
meric nanoparticles, or polymersomes [6–10]. Encapsulation of therapeutic compounds in 
drug delivery systems improve their solubility and protect them from the biological environ-
ment and circumvent the P-gp at the BBB yielding higher concentrations of the therapeutic 
compounds in the brain parenchyma [5]. Among nanocarriers, liposomes have been the most 
studied due to their composition, which makes them biocompatible, biodegradable, and less 
toxic [11]. Liposomes not only hold potential as vehicles for therapeutic compounds (thera-
peutics) [7] but also for diagnostic tools (diagnostics) [12] directed to the CNS. Interestingly, 
recent efforts have combined therapeutics and diagnostics in the same unique nanocarrier, 
thus opening the way to theranostic liposomes, which represent an essential advancement for 
personalized nanomedicine [13]. To specifically target the therapeutic compound or the diag-
nostic tool to the pathological site, the CNS, two strategies are usually used [14]: (1) Passive 
targeting based on the longevity of the pharmaceutical carrier in the blood and its accumula-
tion in pathological sites with compromised vasculature via the enhanced permeability and 
retention effect and (2) Active targeting based on the attachment of specific ligands to nano-
carriers surface to recognize and bind specific biological receptors expressed at the BBB [14]. 
Later studies propose a new active targeting strategy in which liposomes take advantage of 
changes in the pathological microenvironment for localized and timely release of their cargo 
[15]. According to their formulation, stimuli-sensitive liposomes release may obey to internal 
stimuli such as pH, temperature, redox condition, and enzymatic activity or external stimuli 
such as magnetic fields, ultrasound, or irradiation [15]. Since innovative strategies are urgently 
needed to counteract CNS diseases, this manuscript summarizes the most relevant examples of 
passively and actively targeted liposomes, smaller than 200 nm, for therapeutics, diagnostics, 
or theranostics of major CNS diseases.
2. The blood-brain barrier
The blood-brain barrier (BBB) is an innate and selective barrier formed by endothelial cells 
lining ~650 km of microvessels, which constitute by far the largest interface for the blood-brain 
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exchange (Figure 1) [3]. The BBB endothelial cells differ from endothelial cells in the rest of the 
body by the absence of fenestrations and sparse pinocytic vesicular transport. The BBB endo-
thelial cells display wider tight junctions known as zonulae occludens, and adherens junctions 
(AJ), which cover the vessels walls as a continuous sheath, leaving no space between cells [16]. 
Moreover, the BBB is also composed by an extracellular matrix (basal membrane), pericytes, 
and astrocyte foot processes [2, 4]. Because of this configuration, most molecular traffic takes 
a transcellular route across the BBB, rather than moving paracellularly as in most endothelia. 
The presence of specific transport systems on the luminal and abluminal membranes regu-
lates the influx and efflux of various essential endogenous and exogenous substrates [17, 18]. 
Small gases such as oxygen and carbon dioxide but also small lipophilic agents, such as etha-
nol, caffeine, nicotine, and drugs like anesthetics and barbiturates, can diffuse freely through 
the lipid membranes [19]. Small polar molecules, such as glucose, amino acids, organic anions 
and cations, and nucleosides cross the BBB by carrier-mediated transport. Large solutes, such 
as proteins and peptides, are transported across the BBB by receptor-mediated or adsorption-
mediated endocytic transport [17, 18]. In parallel, it was originally stated that therapeutic 
compounds transporting across the BBB were dependent on their physicochemical properties 
such as lipophilicity, molecular weight, and ionic state. However, it is the presence of efflux 
Figure 1. The blood-brain barrier. P-gp = P-glycoprotein, MRP = Multidrug resistance-associated proteins, BCRP = Breast 
cancer resistance protein, and OATP = Organic anion transporter polypeptide.
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transporters at the BBB that limits the brain uptake of a variety of endogenous and exogenous 
compounds, including relatively lipophilic therapeutic compounds [20]. Most of these efflux 
transporters belong to the ATP-binding cassette (ABC) transporters super family. ABC trans-
porters are transmembrane proteins that use the energy from the ATP hydrolysis to drive the 
efflux of their substrates. Based on three critical defining criteria, multi-specificity, location, 
and energetics; P-glycoprotein is considered to be the most important ABC efflux transporter 
at the BBB [21].
3. The P-glycoprotein
The expression of P-glycoprotein (P-gp) on endothelial cells at the human BBB was first 
described in 1989 by Cordon-Cardo et al. and Theibaut et al. [22, 23]. Since then, P-gp has 
been found at the luminal membrane of the endothelial cells lining the capillaries of the brain 
[4, 24], in neurons and in astrocytes [25, 26]. The P-gp is also localized at the apical surfaces 
of the epithelial cells that constitute the ventricular exposed surface of the human choroid 
plexus [27]. The P-gp was also observed in primary brain tumors [28]. The relevance of the 
P-gp at the BBB has been properly illustrated in knockout mice lacking the P-gp isoform 
mdr1a (mdr1a (−/−) mice). The mdr1a (−/−) mice were healthy and fertile and appeared phe-
notypically normal, but they accumulated much higher levels of P-gp substrates in the brain. 
A clear example was the increased sensitivity to the centrally neurotoxic pesticide ivermectin 
[29]. Knockout mice accumulated 100-fold higher concentrations of ivermectin in the brain as 
compared to wild-type mice; consequently, knockout mice developed a severe neurotoxicity 
and died [29]. More recently, selamectin, another pesticide also demonstrated to be a P-gp 
substrate [30]. Meanwhile, pharmacokinetic studies in knockout mice were rapidly extended 
to therapeutic drugs. Thus, the absence of mdr1a in mice led to highly increased levels of 
vinblastine, digoxin, and cyclosporin A in the brain [31]. Tissue distribution studies dem-
onstrated that the relative brain penetration of radiolabeled ondansetron and loperamide is 
increased 4- and almost 14-fold, respectively in mdr1a (−/−) mice. Moreover, a pilot toxicity 
study showed that the oral administration of loperamide gains potent opiate-like activity in 
the CNS of mdr1a (−/−) mice. Oral domperidone also showed neuroleptic-like side effects in 
mdr1a (−/−) mice [31]. Using the same in vivo model, it was suggested that antidepressants like 
levomilnacipran, vilazodone, and escitalopram are P-gp substrates [32], while the modern 
antiepileptic topiramato is only a weak P-gp substrate [33]. These observations are strongly 
supported by brain distribution and disease models not only for the above drugs but also for 
a large list of them [2].
4. Circumventing the BBB
Disruption of the BBB has been observed in various CNS pathologies such as stroke, mul-
tiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS) [34]. From these scenarios, it 
is known that disruption of the BBB leads to increased extravasation of immune cells and 
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poorly regulated flux of molecules and ions across the BBB with consequent neuroinflam-
mation, neurodegeneration, or infections [35]. Additionally, clinical disruption of the BBB 
is expensive and requires hospitalization [7]. Therefore, in diseases where the BBB repre-
sents an obstacle to attain significant brain concentrations of therapeutic compounds, a less 
aggressive alternative is by modulating the activity of the P-gp. Nonetheless, we cannot 
negligate that the P-gp protects the brain from intoxication by endogenous and exogenous 
harmful lipophilic compounds that otherwise could penetrate the BBB by simple diffusion 
without any limitation [36]. Therefore, the ideal approach should inhibit the P-gp at the BBB 
to let the P-gp substrate (therapeutic compound) enter into the brain and then re-induce the 
P-gp-mediated efflux to hamper the entry of harmful compounds. The development of third-
generation P-gp modulators, which transiently and directly inhibit the transport of P-gp 
substrates, has been a promising approach to modulate the P-gp [37, 38]. Unfortunately, 
clinical studies suggest high doses of these compounds. These high doses by themselves or 
in co-administration with P-gp substrates may predict toxic profiles, thus limiting the use 
of these agents [39]. Several studies have already proposed the use of natural products, the 
designs of peptidomimetics, and dual activity ligands as a fourth-generation of P-gp modu-
lators [40]. In spite of the countless studies, the effective and safe inhibition of the P-gp at 
the human BBB is not yet a reality. A non-invasive strategy that takes advantage of the CNS 
physiology involves nanomedicine [41]. This innovative strategy uses mainly nano-scale 
drug delivery systems (DDSs) such as liposomes, polymeric nanoparticles, lipid nanocap-
sules, and polymersomes. Hereafter, DDSs transport small doses of poorly soluble drugs 
through the body and by-pass the P-gp at the BBB to finally target the brain, thus reduc-
ing toxicity in peripheral tissues [5]. A synergistic strategy that had obtained optimistic 
in vivo results tackling the P-gp at the BBB is the concomitant loading of a P-gp substrate 
and a P-gp inhibitor in the same nanocarrier [42]. Nanomedicine also offers the possibility to 
transport diagnostic tools as well, thus providing clear benefits to diagnose and treat defiant 
diseases [43]. Owing to their unique characteristics like biocompatibility, biodegradability, 
non-inmunogenicity, and less toxicity, liposomes have been the most studied and clinically 
recognized among nanocarriers [11].
5. Liposomal strategies to target the central nervous system
Nanotechnology is the understanding and control of matters having dimensions roughly 
within the 1–100 nm range. However, in nanomedicine, particles smaller than 10 nm are 
quickly cleared by the kidney or through extravasation and particles bigger than 200 nm 
are efficiently filtered by liver, spleen, and bone marrow, thus a size between 10 and 200 nm 
would enable liposomes to circulate in the bloodstream [44]. Due to their structure, liposomes 
have demonstrated their ability as nanocarriers for CNS targeting of hydrophilic or lipophilic 
cytotoxics, neuroprotectants, antiepyleptics, anti-ischemia, antiretroviral and antifungals 
drugs among others, and diagnostic agents. Basically, liposomes deliver their cargo across 
the BBB through passive and active targeting (Figure 2). Nonetheless, active targeting goes 
further, opening a stimuli-responsive strategy.
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5.1. Passive targeting strategy
Passive targeting is mainly based on the enhanced permeability and retention (EPR) effect. 
In 1986, Maeda and co-workers named EPR effect to the mechanism in which macromol-
ecules with a high molecular weight, 15000 to 70000 daltons, such as polymers and proteins 
precipitate and accumulate effectively in tumor tissues [45]. Such high accumulation usually 
last more than 24 hours [45]. This phenomenon was attributed to the hypervasculature and 
enhanced vascular permeability in solid tumors, which is due to the overproduction of vas-
cular mediators including bradykinin, nitric oxide (NO), vascular endothelial growth factor 
(VEGF) and carbon monoxide (CO) [46]. Moreover, solid tumors have defective blood vessels 
with large gaps, up to 1.0 μm between endothelial cells, whereby macromolecules pass to the 
tumor [14]. Since solid tumors lack adequate lymphatic drainage, there is therefore a poor 
circulatory recovery of the extravasated macromolecules, resulting in their accumulation in 
the tumor microenvironment for long periods [14]. This phenomenon was not observed in 
healthy blood vessels [45]; hence, it constituted a promising strategy to treat selectively can-
cer solid tumors using nanocarriers like polymer-coated liposomes [47]. Prolonged blood 
circulation may allow a longer interaction time between liposomes and the target. The incor-
poration of soluble, hydrophilic, flexible and biocompatible polymers such as polyethylene 
glycol (PEG) or its derivatives within the bilayer of conventional liposomes leads to the for-
mation of a protective and hydrophilic layer on their surface. This prevents the recognition 
Figure 2. Liposomal strategies for passive and active targeting.
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of liposomes by opsonins and reduces their clearance by the reticuloendothelial system (RES) 
and consequently extends the liposomal half-life [48]. Other prominent synthetic polymers 
with stealth properties are poly(vinyl pyrrolidone) (PVP) and poly(acryl amide) (PAA) [11]. 
Liposomes size is another parameter with high impact on the passive targeting through the 
EPR effect. Long-circulating liposomes also called stealth liposomes should possess a size 
inferior to 400 nm for effective extravasation [14, 48]. Different studies demonstrated that 
passive targeting provides promising therapeutic outcomes in diseases where there is a BBB 
disruption like stroke [49, 50].
5.2. Active targeting strategy
In the last few years, more sophisticated liposomes were designed to actively target the 
brain. Active targeting lies on the coupling of targeting moieties including small-molecule 
ligands, peptides, aptamers, monoclonal antibodies (mAbs) or their fragments on the liposo-
mal surface. Then these functionalized liposomes are able to target the brain after recogniz-
ing the biochemical transport systems expressed at the brain endothelial cells. Such systems 
are the adsorptive-mediated endocytosis (AME), the carrier-mediated transport (CMT), and 
the receptor-mediated endocytosis (RME). Brain targeting through AME is based on the elec-
trostatic interaction between a positively charged moiety and the negatively charged sites 
on the luminal surface of plasma membrane and brain capillaries. For instance, cationized 
human serum albumin conjugated to PEGylated liposomes showed a rapidly time-depen-
dent response taken up by cultured porcine brain capillary endothelial cells and by intact 
brain capillaries [51]. However, in vivo, AME also occurs to a large extent in other organs like 
liver and kidneys, thus decreasing brain specificity [6]. The CMT systems are localized at the 
brain capillary endothelium and mediate the passage of small molecular weight nutrients 
across the BBB. The most studied are the transporters for D-glucose (GLUT1), large neutral 
amino acid (LAT1), small neutral amino acids (EAAT), cationic amino acids (CAT1), mono-
carboxylic acids (MCT1), and organic cations (OCT) [52]. Although a possible competition 
with endogenous ligands is predicted, liposomes decorated with LAT1 were able to pen-
etrate the BBB penetration in vivo [53]. RME is one of the major mechanisms by which various 
DDSs can deliver their cargo across the BBB. RME systems require the binding of a ligand to 
a specific receptor located on the luminal membrane of the BBB [6]. Then, the receptor-ligand 
binding induces the internalization of receptor-ligand complexes within an endocytic vesicle. 
From there forward, receptors may mediate different processes including: (1) transcytosis of 
the ligand from blood to brain, (2) reverse transcytosis from brain to blood, or (3) only endo-
cytosis into the brain capillary endothelium without net transport across the endothelial cell 
[52]. Specific receptors of the brain capillary endothelium have been identified for low-den-
sity lipoproteins (LDL), low-density lipoprotein receptor-related protein 1 (LRP-1), insulin, 
insulin-like growth factors (IGF-I, IGF-II), interleukin-1 (IL-1), folic acid (FA) and transferrin 
(Tf) [52]. Hence, attachment of these endogenous ligands to the surface of liposomes has gen-
erated promising results [54]. Besides binding endogenous ligands, these receptors also bind 
mAbs or their fragments (Fab’, F(ab’)
2
), which could be grafted on the liposomes surface [6]. 
The most successful mAb that has been studied and used for brain targeting is OX26 [55, 56], 
which specifically targets brain capillary endothelial cells, thanks to the high concentration 
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of the transferrin receptor (TfR) expressed on their luminal side [57]. Thus, OX26 may be able 
to cross the BBB via the receptor-mediated transcytosis. OX26 does not bind the TfR on the 
transferrin-binding site but uses another epitope [58]. Given that high doses of insulin are 
required to target the insulin receptor and that an overdose of insulin could cause hypogly-
cemia, some studies effectively promote grafting of liposomes with the murine 83–14 mAb to 
target the BBB via the insulin receptor [59]. The low-density lipoprotein receptor (LDLR) and 
the LDLR-related protein (LRP) can bind multiple ligands. Among them, the apolipoprotein 
E grafted to liposomes favored the internalization of the DDS via the LDLR in porcine brain 
capillary endothelial cells and the rodent cell line RBE4 [60]. Moreover, increased expression 
of epidermal growth factor receptor (EGFR) [61], vascular endothelial growth factor recep-
tor (VEGFR) [62] and integrins [63] in the brain environment is associated with brain injury 
or blood-brain barrier (BBB) dysfunction, thus providing more targets in these pathological 
episodes.
5.3. Stimuli-responsive strategy
Usually the challenge is to formulate liposomes which have the right size and structure to 
entrap their cargo with high efficiency and in such a way that they do not leak out. On the 
other hand, it is important to play on the fluidity of the liposomal membrane. A too high 
liposomal stability is rather disadvantageous than desired. Remaining inside the stable lipo-
somes, the encapsulated compounds are not delivered to the targeted tissue. At that point, it 
is necessary to find the right balance between stability in the bloodstream and a high delivery 
of liposomal cargo in the target. In general, the chemical and biophysical properties of lipid 
molecules primarily dictate the development of tunable (stimuli-sensitive) liposomes [64]. 
The various types of stimuli that could trigger liposomal cargo release can be classified into 
internal or intrinsic to the target tissue (changes in pH, temperature, redox condition, or the 
activity of certain enzymes) and external or artificially applied (magnetic field, ultrasound, 
and various types of irradiation) [15]. In one example, the lower pH, the higher temperature, 
and overexpression of several proteolytic enzymes of the tumor microenvironment should 
trigger the cytotoxic release when liposomes are exposed [14]. More exhaustive literature 
about stimuli-sensitive liposomes was formerly described [14, 15].
The encapsulation of nanoparticles in liposomes not only adds more stimuli for delivery but 
also provides more useful properties. For instance, by encapsulating PEG-coated quantum 
dots (QDs) in the internal aqueous phase of liposomes, a more extensive fluorescent staining 
is observed in a solid tumor model compared to free PEGylated QDs [65]. Meanwhile, super-
paramagnetic iron oxide nanoparticles (SPIONs) loaded in liposomes demonstrated to serve 
as a magnetic resonance imaging in vivo tool [66].
6. Liposomes for drug delivery to the central nervous system
More recent and relevant studies applying different liposomal targeting strategies for the 
treatment of major CNS diseases are summarized herein.
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6.1. Stroke
An ischemic stroke occurs because of an obstruction, by a blood clot, within a blood vessel 
supplying blood to the brain [67]. Ischemic stroke accounts for 87% of all stroke cases. The 
cerebral ischemic area is composed of the ischemic core, a zone of irreversibly damaged tissue, 
and the ischemic penumbra, a surrounding zone of less severe and reversible damaged tissue 
[67]. To date, the only Food and Drug Administration (FDA) approved treatment for ischemic 
stroke is tissue plasminogen activator (tPA), a proteolytic enzyme. tPA enhances the conver-
sion of plasminogen to plasmin, which subsequently degrades the fibrin matrix in the clot and 
improves blood flow to the ischemic region [68]. However, its short half-life, 2–6 minutes and 
therapeutic time window, less than 4.5 hours, elicite its administration in high doses which 
might lead to significant hemorrhagic complications [69, 70]. Interestingly, hemorrhage was 
reduced when tPA was loaded in actin-targeted liposomes and intravenously administered 
by the internal carotid artery in an in vivo model bearing clots injected [71]. Other therapeu-
tic approaches have focused on protecting neurons from the main pathogenic mechanisms 
causing ischemic injury in the penumbra, such as excitotoxicity, oxidative stress, inflamma-
tion, or apoptosis [67]. Certainly, loading of these neuroprotective agents in liposomes may 
return improved results. Various studies emphasized on passive targeting strategies because 
during stroke the BBB is disrupted. Therefore, the effect of intravenous administration of 
empty [3H]-labeled PEG-liposomes in a stroke rat model was investigated [50]. One hour after 
middle cerebral artery occlusion (MCAO), rats received the liposomal formulation and one 
hour after, reperfusion was started (t-MCAO) [50]. [3H]-labeled PEG-liposomes accumulated 
in the ischemic brain in a time-dependent manner. Such accumulation at 3 hours post-dosing 
was significantly higher compared to the one in the non-ischemic side. These results were 
attributed to the disruption of the BBB and the leakage of liposomes to the brain parenchyma, 
where they gradually accumulated in the ischemic region via the EPR effect. Usually, once 
reperfusion is started, secondary cerebral damage known as ischemic/reperfusion (I/R) injury 
is observed [50]. In the same study, intravenous administration of PEGylated liposomes 
loaded with tacrolimus, a neuroprotective agent and a P-gp substrate [2] before (I/R) injury 
significantly suppressed cerebral cell death. While the damage volume for PEG-liposomes 
encapsulating tacrolimus was about 0.2 cm3; for free tacrolimus and PBS, it was  0̴.3 and  0̴.4 
cm3, respectively. This formulation also suppressed superoxidative anions induced-damage 
in the brain and improved motor function deficits compared to free tacrolimus [50]. Fasudil, a 
Rho-kinase inhibitor is an approved drug for cerebral vasospasm after subarachnoid hemor-
rhage but thanks to its neuroprotective properties, it could be a promising candidate for the 
treatment of ischemic stroke. Phase III clinical trials showed fasudil usefulness and safety 
[72], however, the clinical trials were finished because of fasudil poor clinical efficacy, short 
permanence in the bloodstream and difficulty to penetrate the BBB [49]. Hence, it was encap-
sulated in PEG-liposomes and intravenously administered immediately after reperfusion in 
t-MCAO rats [49]. Fasudil-loaded PEG-liposomes diffused and accumulated in the I/R region, 
from an early phase after administration up to 24 hours. Moreover, the aforementioned for-
mulation significantly suppressed the volume of damaged brain tissue, obtaining  0̴.2 cm3, 
compared to free fasudil,  0̴.3 cm3, and PBS,  0̴.4 cm3. Fasudil-loaded PEGylated liposomes 
also reduced in a significant manner neutrophil invasion and improved the motor functional 
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disorder [49]. The success of this study was basically due to PEGylation and liposome size. 
Using the same stroke in vivo model, it was confirmed that  ̴100 nm PEG-liposomes got a high 
accumulation on the ischemic side,  2̴00 nm PEG-liposomes showed a lower accumulation 
and no accumulation was observed for  8̴00 nm PEG-liposomes [49]. Xenon is a pleiotypic 
cytoprotective gas, which rapidly diffuses across the BBB. Although xenon has few clinical 
adverse effects, its administration by inhalation requires intubation and ventilation with a 
large xenon concentration that reduces the maximum fraction of inspired oxygen [73]. Thus, 
an ultimate study encapsulated xenon into echogenic liposomes and determined its benefits 
after systemic administration in t-MCAO rats. Different dosage schemes demonstrated that 
this formulation effectively reduced ischemic neuronal cell death and improved neurological 
function. Undoubtely, ultrasound triggered additional liposomal xenon release obtaining still 
better therapeutic results [73]. Other studies accentuate on the benefits of actively targeted 
strategies over passively targeted strategies during stroke (Table 1). For instance vascular 
endothelial growth factor (VEGF) was loaded in PEGylated liposomes decorated with trans-
ferrin and intravenously administered two days after inducing a t-MCAO model [74]. VEGF 
confers neuroprotection, promotes neurogenesis and cerebral angiogenesis, and transferrin is 
an iron-binding glycoprotein with high affinity for the transferrin receptor (TfR) at the BBB 
[75]. While the damage volume for VEGF-loaded PEGylated liposomes coupled to transferrin 
was about  2̴.5 cm3, for VEGF-loaded PEGylated liposomes was   3̴.0 and for saline  3̴.5 cm3, 
respectively. VEGF-induced neovascularization in the penumbra zone was significantly 
higher for the actively targeted formulation (245,873 microvessels per field), than for the pas-
sively targeted formulation (139,801.3) and for saline (102,175.5) [74].
6.2. Cancer
Globocan 2012 revealed that the worldwide brain and CNS cancer incidence and mortality 
in both sexes was 3.4 and 2.5 per 100,000 people, respectively [76]. In parallel, the World 
Cancer Research Fund International (http://www.wcrf.org) estimated that 256,000 new cases 
of brain and CNS cancer were diagnosed in 2012. Gliomas are tumors that arise from glial or 
precursor cells and include astrocytoma, glioblastoma, oligodendroglioma, ependymoma, 
mixed glioma, malignant glioma, and a few rare histologies. Glioma accounts for 27% of 
all tumors and 80% of malignant tumors, and among these, glioblastoma is the most com-
mon accounting for 46.1% [77]. Unfortunately, the efficacy of conventional chemotherapy is 
always limited due to the poor specificity in targeting cancer, low circulation time, reduced 
penetration in the tissue, and most importantly the toxic side effects of anti-cancer drugs 
[78]. Thus, nanotechnology appeared to help chemotherapy to be reborn and Doxil®, lipo-
somal doxorubicin, received the first approval as a nano-drug in 1995 [79]. Nowadays, sev-
eral research groups are developing nanocarriers to encapsulate anti-cancer drugs and fight 
against cancer tumors. Owing to the leaky nature of the tumor-associated blood vessels and 
lack of adequate lymphatic drainage, nanocarriers may take advantage of the EPR effect to 
target tumors [14]. However, in the case of brain tumors, nanocarriers must first overcome 
the BBB, which remains intact at the early stage of the brain tumor development. Only when 
the tumor grows to a certain volume and angiogenesis begins, the BBB is impaired and the 
blood-brain tumor barrier (BBTB) then becomes the main obstacle that nanocarriers must 
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Disease Year Size (nm) Targeting ligand Drug/diagnose agent Administration 
route
Results Refs.
Stroke 2015 ̴100 HAIYPRH (T7) 
peptide
ZL006 Intravenous Increased liposomal transport across 
the BBB, reduced infarct volume and 
improved neurological deficit
[117]
2013 ̴160 Anti-NR1-receptor 
antibody
Superoxide dismutase 
enzyme
Intracarotid Reduced infarct volume, inflammatory 
markers, and improved in vivo behavior
[118]
2010 60–90 p-aminophenyl-α-
d-mannoside
CDP-Choline Intravenous Reduced ischemia-reperfusion in young 
and aged animals
[119]
2010 ̴105 Transferrin VEGF Intravenous Reduced infarct volume and increased 
neovascularization
[74]
2003 200–250 Antiactin antibody tPA Intravenous Reduced tPA-induced hemorrhage [71]
2013 ̴100 Anti-HSP72 
antibody
Citicoline/gadolinium 
or rhodamine
Intravenous Increased liposomal transport across the 
BBB and reduced infarct volume
[120]
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Disease Year Size (nm) Targeting ligand Drug/diagnose agent Administration 
route
Results Refs.
Cancer 2016 ̴110 PTD peptide Epirubicine and 
celecoxib
Intravenous Increased liposomal transport across the 
BBB, survival time and anti-vasculogenic 
mimicry effects
[121]
2015 100-120 R8-dGR peptide Paclitaxel Intravenous Increased survival time [122]
2015 ̴110 R8-c(RGD) Paclitaxel Intravenous Increased survival time and anti-
vasculogenic mimicry and anti-brain 
cancer stem cells effects
[123]
2014 ̴95 Glutathione Doxorubicin Intravenous Increased doxorubicin levels in brain, 
tumor growth inhibition, and increased 
survival
[81]
2014 ̴100 Glutathione Doxorubicin Intravenous Increased doxorubicin levels in brain [83]
2014 105 WGA Daunorubicin, 
quinacrine and 
tamoxifen
Intravenous Increased liposomal transport across the 
BBB and survival time
[124]
2014 ̴120 RGD and 
transferrin
Paclitaxel Intravenous Increased liposomal transport across 
the BBB and antiproliferative activity 
against C6 cells
[125]
2013 ̴180 Transferrin and 
folate
Doxorubicin Intravenous Increased tumor growth inhibition, 
survival time, and apoptotic activity in 
glioma cells
[54]
2009 100-110 WGA Topotecan and 
tamoxifen
Intravenous Increased survival time [86]
2015 ̴100 pH-sensitive valve Gd-DTPA Intravenous Improved cargo release in tumor 
microenvironment
[126]
2014 ̴120 Endoglin Gd Intravenous Increased signal emmited by Gd in 
tumor periphery
[127]
2016 ̴180 (RGD-TPGS Docetaxel/QD Intravenous Increased docetaxel levels and QD 
fluorescence in brain
[128]
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Disease Year Size (nm) Targeting ligand Drug/diagnose agent Administration 
route
Results Refs.
AD 2015 ̴200 Transferrin α-Mangostin Intravenous Increased α -mangostin levels in brain [129]
2015 ̴110 Glutathione Amyloid-targeting 
antibody fragments
Intravenous Increased amyloid-targeting antibody 
fragments levels in plasma and brain
[130]
2013 ̴180 CPP Rivastigmine Intranasal Increased rivastigmine levels in 
hippocampus and cortex
[92]
2012 ̴150 DSPE-PEG3400-XO4 DSPE-PEG3400-XO4 Intravenous Liposomal transport across the BBB and binding to Aβ plaques
[131]
PD 2012 ̴120 OX26 GDNF Intravenous A partial rescue of nigra-striatal neurons [104]
2011 ̴110 Chlorotoxin L-dopa Intraperitoneal Increased dopamine levels in substantia 
nigra and striata and attenuated 
behavioral disorders
[102]
Abbreviations: CDP-Choline = cytidine 5′ diphosphocholine, VEGF = vascular endothelial growth factor, tPA = tissue plasminogen activator, PTD = glycine-arginine-
lysine-lysine-arginine-arginine-glutamine-arginine-arginine-arginine-cysteine-glycine-NH
2
 peptide, RGD = arginine-glycine-aspartic acid peptide, WGA = wheat germ 
agglutinin, Gd-DTPA = gadolinium-diethylendiaminopentaacetic acid, Gd = gadolinium, RGD-TPGS = arginine-glycine-aspartic acid peptide-D-alpha-tocopheryl 
polyethylene glucol 1000 succinate, QD = quantum dots, CPP = cell penetrating peptide, DSPE-PEG3400-XO4 = 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy-XO4-(polyethylene glycol-3400)] sodium salt and GDNF = glial-derived neurotrophic factor.
Table 1. Recent studies based in active targeted liposomes for CNS diseases.
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circumvent. Hence, the presence of receptors on the BBB and BBTB provides a pathway 
to actively target brain tumors (Table 1) [80]. A recent in vivo study showed the difference 
between passive and active brain targeting of doxorubicin, a P-gp substrate [2]. PEGylated 
liposomal [14C]-labeled doxorubicin similar to Doxil®/Caelyx® was used as the passive tar-
geting formulation, whereas Glutathione PEGylated liposomal [14C]-labeled doxorubicin 
(2B3-101) was assessed as the active delivery system [81]. Glutathione is an endogenous tri-
peptide currently used as a drug-targeting ligand because among the nutrient transporters 
in mammalian species, glutathione transporter has a preferential expression at the BBB [82]. 
After intravenous administration, both liposomal formulations displayed a similar doxo-
rubicin pharmacokinetic profile and brain exposure during the first 24 hours. However, 4 
days post-dosing, the brain doxorubicin concentration as well as its brain-to-plasma ratio 
was higher for Glutathione PEGylated liposomes. Compared to passive liposomes, active 
liposomes resulted in a significant inhibition of tumor growth and two animals of this group 
showed a complete tumor regression. Moreover, the active delivery system exhibited an 
increase of 16.1% in the median survival compared to the passive delivery system and an 
increase of 38.5% compared to saline [81]. Later, the same research group, using the sophis-
ticated cerebral open flow microperfusion (cOFM) brain sampling technique, found that 
Glutathione PEGylated liposomes enhanced doxorubicin concentration in the brain extracel-
lular space  ̴5-fold relative to PEGylated liposomes [83]. 2B3-101 was recently investigated 
in a phase I/IIa clinical study in patients with solid tumors, brain metastases, or recurrent 
malignant glioma (www.clinicaltrials.gov). Another approach emphasized on doxorubicin 
loaded liposomes dually functionalized with transferrin and folate to actively target an in 
vivo brain C6 glioma-bearing model [54]. While transferrin binds the TfR at the BBB [75], 
folate or folic acid binds the folate receptor (FR) [84], which is over-expressed in a wide vari-
ety of human tumors and whose density increases as the stage of cancer worsens [84]. After 
four intravenous administrations in 17 days, the mean survival time was 30 days for rats 
treated with this active targeting formulation, 27 days for doxorubicin-loaded liposomes, 24 
days for doxorubicin solution and 20 days for saline. Doxorubicin-loaded liposomes func-
tionalized with transferrin and folate also exhibited the least tumor area and the highest 
apoptotic activity in the glioma cells among all the treated groups [54] and did not modify 
liver enzyme levels or heart histology [54]. Due to its active targeting mechanism of receptor-
mediated endocitosis and its high affinity for the cerebral capillary endothelium, wheat germ 
agglutinin (WGA) showed to be a good candidate to target the BBB [85]. Grafted to the sur-
face, WGA favored the transfer of topotecan-tamoxifen-loaded liposomes across the BBB and 
then targeted brain tumors [86]. Among the four types of topotecan liposomes with or with-
out the P-gp modulator tamoxifen and/or WGA, the one modified with tamoxifen and WGA 
exhibited the strongest cytotoxic effect against murine glial tumor (C6) cells [86]. Likewise, 
this formulation achieved the highest inhibitory effect against C6 cells after crossing an in 
vitro BBB (murine brain microvascular endothelial cells/rat astrocytes) model [86]. Moreover, 
after one week of treatment with the different formulations, the mean survival time of an 
in vivo brain C6 glioma-bearing model was 26 days for topotecan liposomes modified with 
tamoxifen and WGA, 20 days for topotecan liposomes, 19 days for free topotecan and 15 
days for saline. A mean survival time of 31 days was achieved with two weeks of treatment 
with topotecan liposomes modified with tamoxifen and WGA [86].
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6.3. Alzheimer’s disease
Alzheimer’s disease (AD) is the most common neurodegenerative dementia and contributes 
to 65% of all cases. AD is substantially increased among people aged 65 years or older, lead-
ing to progressive decline in memory, thinking, language, and learning capacity [87]. The 
pathophysiology of AD is related to the injury and death of neurons caused by the progres-
sive production and accumulation of insoluble proteins aggregates, such as amyloid-β (Aβ) 
plaques and neurofibrillary tangles of hyperphosphorylated tau [88]. Currently, there is 
no drug to treat AD; only four FDA-approved compounds are known to relieve AD symp-
toms. These are donepezil, galantamine, memantine, and rivastigmine [89]. Once donepezil, 
a weak P-gp substrate [90], was encapsulated in PEGylated liposomes and administered 
by intranasal route in experimentation animals, it exhibited higher plasma and brain con-
centrations than free donepezil administered by the same or oral route [91]. In addition, 
histopathological examination showed that PEGylated liposomal donepezil was safe and 
non-toxic [91]. Rivastigmine was encapsulated in PEGylated liposomes functionalized with 
a cell penetrating peptide (CPP), whose proved internalization pathway across the cell 
membrane is via transduction or endocytosis [92, 93]. This formulation administered by 
intranasal route demonstrated its capacity to improve rivastigmine distribution and reten-
tion in the hippocampus and cortex, which are CNS regions highly affected by AD. This is 
in comparison with the intravenous administration of rivastigmine solution [92]. The clini-
cal utility of galantamine, which is also a P-gp inhibitor [94], is hampered by its intricate 
transport across the BBB and its poor retention in the CNS. Hence, galantamine was loaded 
in PEGylated liposomes functionalized with a synthethic peptide, Lys-Val-Leu-Phe-Leu-Ser 
[95]. The selected peptide possess a 75% similar sequence to the serpin enzyme complex-
receptor (SEC-R), which is expressed on the surface of neural (PC12) cells and may interact 
with soluble and non-toxic Aβ-peptides [96]. Thus, fluorometry and confocal microscopy 
confirmed that actively targeted liposomes significantly facilitated a higher uptake and 
accumulation of galantamine in PC12 neuronal cells related to non-targeted PEGylated lipo-
somes [95]. The utility of neuroprotective agents in AD was also optimized by encapsulating 
them in actively targeted liposomes (Table 1).
6.4. Parkinson’s disease
Parkinson’s disease (PD) is the second most common progressive neurodegenerative brain 
disorder of insidious onset. This chronic disease is caused by a selective degeneration of 
dopaminergic neurons in the substantia nigra pars compacta, which consequently results in 
a reduction in striatal dopamine levels [97]. PD is generally characterized by primary motor 
symptoms such resting tremor, bradykinesia, rigidity, and postural instability. Non-motor 
symptoms experienced by PD patients may include cognitive impairment, mood disorders, 
and sleep disturbances [98]. Up-to-date, there is no cure for PD, the only available treatment, 
dopamine, is focused on the signs and symptoms. Since exogenous dopamine cannot cross 
the BBB, the gold standard therapy for PD is based on the administration of the natural pre-
cursor of dopamine, L-dopa, to restore dopaminergic transmission [99]. Because L-dopa is 
a P-gp substrate [100], it only crosses the BBB to a certain extent and once in the brain, it is 
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converted to dopamine. However, L-dopa cannot be administered alone because it is cata-
lyzed to dopamine by peripheral dopamine-decarboxylase enzyme and causes peripheral 
side effects, such as nausea, sleepiness, and dyskinesia [99]. Thus, L-dopa was encapsulated 
in PEGylated and chlorotoxin-functionalized liposomes and studied in an in vivo 1-methyl-
4-phenyl-1,2,3,6-tetrahydro pyridine (MPTP)-induced PD model [101]. Chlorotoxin (ClTx) is 
a 36-amino acid peptide that exhibits high affinity for brain gliomas and other tumors of 
neuroectodermal origin [102] but it is also able to bind proliferating vascular endothelial cells 
[103]. After intraperitoneal injection, the aforementioned formulation significantly increased 
the distribution of dopamine in the substantia nigra and striata and attenuated the behavioral 
disorders. Besides, it diminished the MPTP-induced loss of tyrosine hydroxylase-positive 
dopaminergic neurons as compared with L-dopa in PEGylated liposomes and free L-dopa 
[101]. Glial-derived neurotrophic factor (GDNF), a rescue of nigra-striatal tract agent was 
encapsulated in PEGylated liposomes functionalized with the mAb OX26 and administered 
in a 6-hydroxydopamine-induced PD in vivo model [104]. Authors explained the partial res-
cue of the nigra-striatal tract through the two weeks delayed and single liposomal intravenous 
administration, thus suggesting that future studies should increase and timely synchronize 
dosing administration with the onset of the disease [104].
6.5. Epilepsy
Epilepsy is a chronic and often progressive brain disorder, characterized by recurrent sei-
zures, which are brief episodes of involuntary movement involving a part or the whole 
body. These episodes are caused by excessive electrical discharges from cortical neurons, 
which can cause visual disturbances, loss of control of bowel or bladder function, and con-
sciousness [105]. According to the World Health Organization, epilepsy affects about 50 
million people worldwide but only 70% of patients can be successfully treated while about 
30% of patients are resistant or refractory to current available antiepileptics [106]. Earlier 
research has shown that mainly the activity of the P-gp at the BBB is directly related to 
anticonvulsants resistance [107]. This so-called medically intractable epilepsy is often asso-
ciated with a poor prognosis, increased morbidity and mortality in patients, and a negative 
social impact in the life of patients and their family environment [106]. Unfortunately, only 
few studies have tried to improve the epilepsy therapy by applying nanotechnology. In a 
pilocarpine-induced seizure in vivo model, nimodipine, a neuroprotective agent [108] and 
a P-gp substrate [109] encapsulated in liposomes prevented epileptic seizures and mortal-
ity compared to free nimodipine [110]. In the meantime, curcumin, another neuroprotec-
tive agent [111] with ability to inhibit the P-gp [112], encapsulated in liposomes delayed 
the onset and decreases the duration of epileptic seizures in a pentylenetetrazole-induced 
seizure in vivo model [113]. In the same way, the anticonvulsivant activity of gossypin, a 
bioflavonoid isolated from Hibiscus vitifolius and possible P-gp inhibitor [114], was signifi-
cantly improved when it was entrapped in liposomes. Liposomal gossypin succeeded in 
increasing seizures threshold and latency of current electroshock seizures pentylenetetra-
zole-induced seizure in vivo model [115]. Earlier studies demonstrated that liposomal anti-
convulsivants as valproic acid and phenytoin exerted more prominent therapeutic efficacy 
than free drugs [116].
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7. Liposomes for diagnostics of central nervous system diseases
Liposomes by themselves do not have any imaging property but various efforts have enabled 
liposomes to entrap and deliver diagnostic agents in pathological tissues. Most investigations 
deal with diagnosis of cancer.
7.1. Cancer
By attaching synthetic pH-responsive chemical modulators to an Escherichia coli mechanosen-
sitive ion channel of large conductance (MscL), it was properly converted in a pH-sensitive 
valve able to gate at acidic environments such as solid tumors, sites of inflammation, endo-
somes, and lysosomes [132]. The sensitivity and pH interval for channel opening were tuned 
by varying the hydrophobicity and pK
a
 of the pH modulators. At a pH lower than the pKa 
of the modulator, the channel acquires a charge in the pore of the channel, which tends to 
the opening [132]. Later, these pH-sensitive valves were incorporated in PEGylated liposomes 
loaded with paramagnetic chelate gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA), 
which is detectable in vivo by magnetic resonance imaging (MRI). The aforementioned for-
mulation, Gd-DTPA-pH-sensitive PEGylated liposomes was compared to Gd-DTPA-pH-
insensitive PEGylated liposomes in mice implanted with a C6 glioblastoma tumor which has 
a pH between 6.6 and 7.0 [126]. While Gd-DTPA-pH-sensitive PEGylated liposomes started 
to release their cargo ten minutes post-dosing and lasted up to forty minutes, the Gd-DTPA-
pH-insensitive PEGylated liposomes showed a slow initial release that only stabilize after ten 
minutes and was significantly lower than the pH-sensitive formulation. This study demon-
strated that only few ion channels per liposome are sufficient to induce the release of content 
[126]. The strategy used herein is advantageous and highly supported over other pH-sensitive 
liposomes containing high amounts of negatively charged lipids, polymers, or unsaturated 
lipids. These materials make liposomes prone to fast bloodstream clearance affecting basically 
their pharmacokinetic properties and thus those of the encapsulated cargo [126]. Usually, the 
targeting moiety is conjugated to the liposomal surface and the whole formulation is assessed 
in vitro or in vivo. Nonetheless, a two-step active targeting is also possible and it was the case 
for molecular imaging of delineating tumor margins in a C6 glioma-bearing model [127]. 
Herein, the biotin-streptavidin ligation technique was used for its reability to attach antibodies 
on liposomes surface [133]. Gadolinium was used as the imaging agent and endoglin (CD105), 
a protein involved in angiogenesis, was used as the targeting moiety. Hence, experimentation 
animals received an intravenous injection of biotin-endoglin and after 24 hours, injection of 
streptavidin-PEGylated liposomes loaded with gadolinium. In this way, in the tumor periph-
ery, the signal emitted by gadolinium from the two-step targeting was about 59% higher than 
those obtained for the usual one-step targeted liposomes and non-targeted liposomes [127].
8. Liposomes for theranostics of central nervous system diseases
A major achievement of nanomedicine in the last few years was the development of ther-
anostic delivery systems, which integrate imaging and therapeutic functions in one single but 
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complex structure, thus providing a powerful approach to improve disease-specific detection, 
treatment, and follow-up monitoring [134]. The flexible composition of liposomes enables 
them to be engineered to adsorb, entrap, encapsulate, or conjugate different imaging agents 
and therapeutic compounds [134].
8.1. Stroke
Citicoline (CDP-Choline), a drug used in the treatment of stroke [135], was loaded in lipo-
somes made of phospholipids containing rhodamine or gadolinium, which enabled the nano-
carriers to be traceable by fluorescence or MRI. These liposomes were functionalized with 
anti-HSP72 antibody, which is able to bind the HSP72 protein. HSP72 protein is a biomarker 
expressed for up to seven days in the peri-infarct region following cerebral ischemia [120]. 
This formulation was administered by intravenous route after surgery in an MCA in vivo 
model, where it achieved a damage of 30% volume smaller than the one obtained with free 
citicoline. This could be attributed to the 80% traceable liposomal localization on the periph-
ery of the ischemic lesion [120].
8.2. Cancer
Liposomes co-encapsulating the cytotoxic and P-gp substrate docetaxel [2] and QDs and 
actively targeted with arginine-glycine-aspartic acid peptide -D-alpha-tocopheryl polyethyl-
ene glycol 1000 succinate (RGD – TPGS) were developed and tested in vivo for brain targeting 
[128]. QDs are semiconductor nanocrystals with a photostability up to 100–10000 fold greater 
than conventional organic dyes. Unluckily, because QDs are heavy metals, they may lead 
to potential toxicities, but their encapsulation in liposomes may improve their biocompat-
ibility to become a potential tool for diagnostics in in vitro and in vivo tumor models [136]. 
TPGS, a derivative of the natural vitamin E (alpha-tocopherol), has shown great potential 
in overcoming the P-gp via inhibition of its ATPase activity [42]. RGD peptide binds prefer-
entially the αvβ3 integrin, an adhesion molecule highly expressed on activated endothelial 
cells, new-born vessels and some tumor cells [137]. In this context, targeting tumor cells or 
tumor vasculature by RGD-based strategies is a promising approach [138]. Hence, docetaxel-
QDs-loaded liposomes functionalized with RGD-TPGS intravenously administered in rats, 
exhibited a docetaxel brain distribution  ̴2-fold higher than the value obtained for docetaxel-
QDs-loaded liposomes functionalized with TPGS and  ̴7-fold higher than the value obtained 
for free docetaxel [128]. These data is in line with the strongest fluorescence of brain sec-
tions for docetaxel-QDs-loaded liposomes functionalized with RGD-TPGS, mild fluorescence 
for docetaxel-QDs-loaded liposomes functionalized with TPGS and no fluorescence for free 
QDs [128]. Surely TPGS inhibited the P-gp allowing a higher brain distribution of liposo-
mal docetaxel related to free docetaxel [128]. Another study formulated magnetoliposomes 
co-loaded with doxorubicin and SPIONs and coated with carboxymethyl dextran (CMD), a 
stealth alternative to PEGylation [139]. Typically, superparamagnetic nanoparticles coated 
with carboxydextran are used as MRI agents to detect tumors and their microenvironment 
[140]. Thus, in vitro, this formulation demonstrated to be an efficient T
2
-weighed contrast 
agent for MRI but also induced cytotoxicity which could be enhanced by low-frequency 
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alternating magnetic field [139]. Further in vivo data could determine the usefulness of this 
formulation as a potential carrier for targeting diagnostic and therapy to brain cancer.
8.3. Parkinson’s disease
QDs and apomorphine, a rescue medication for Parkinson’s disease were encapsulated in 
PEGylated liposomes [141]. Then, in vivo bioimaging analysis determined that the fluores-
cence emitted from PEGylated liposomal QDs after intravenous administration was higher 
in the brain than in other organs and it lasted up to 60 minutes. In contrast, the fluorescence 
derived from free QDs was visualized immediately following the injection, decreased rapidly 
in the brain but lasted up to 35 minutes in liver [141]. Likewise the brain uptake of liposo-
mal apomorphine at 1 hour post-dosing was 2.4-fold higher than the value obtained for free 
apomorphine. Cell uptake studies in bEND3 cells suggested that these theranostic liposomes 
could enter into cells by clathrin-dependent and caveola-mediated endocytosis [141].
9. Future outcomes
Nanomedicine has emerged as the key to open the door of the medicine of tomorrow. 
Thanks to exponential efforts and improvements, nanomedicine has launched to the clini-
cal field various drug-loaded liposomes for brain targeting (Table 2). However, regarding 
other CNS diseases, nanomedicine has not yet fulfilled its promise. The possible improved 
brain distribution of various liposomal therapeutic compounds and diagnostic agents 
remains to be studied. The CNS is so complex that gives us a wide variety of receptors 
to target. Currently, various targeting moieties such as aptamers, peptides, mAbs, or their 
fragments have proved their ability to target a specific receptor in the CNS. Thus, future 
studies should investigate their in vivo potential but always paying attention to the graft-
ing itself. Attachment of targeting moieties does not alter the liposomal biodistribution; it 
only increases the liposomal internalization in targeted cells. Thus, the quantity of targeting 
Therapeutic compound Purpose: to assess Patients Phase
Cytarabine (DepoCyte®) The safety of whole brain radiotherapy Brain metastases I
Cytarabine The effectiveness in co-administration with 
high doses of methotrexate
SNC metastases II
Doxorubicin The effectiveness Refractory solid brain tumors I
Vincristine (Marqibo) The safety, activity, and pharmacokinetics Refractory solid brain tumors in 
children and adolescents
I/II
Doxorubicin (2B3-101) The safety, tolerability, and 
pharmacokinetics alone or in combination 
with trastuzumab
Solid tumors and brain 
metastases or recurrent 
malignant glioma
I/IIa
Data obtained from www.clinicaltrials.gov
Table 2. Current completed clinical trials based on liposomal formulations for CNS diseases.
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ligand should not compromise the liposomal long-circulating properties conferred by PEG 
or another polymer. The amount of surface PEG-lipid complex necessary for creating stealth 
liposomes varies between 5 and 10 mol% and the optimal PEG-derivative length should 
have a molecular weight of 2000 daltons [142]. If a PEG-derivative is used as the spacer to 
graft the targeting ligand, the amount of PEG molecules to guarantee steric stabilization 
must not be inferior to 5 mol% [143]. Since steric hindrance of the PEG chains may interfere 
with the targeting moiety recognition by the targeted tissue, functionalization of liposomes 
with two PEG chain lengths was proposed. While PEG
2000
 would confer long circulating 
properties, PEG
5000
 would be used as linker to overexpose the targeting ligand to targeted 
cells [56]. To ensure sustained cargo release, an alternative to PEGylation, is the integra-
tion of pre-encapsulated loaded liposomes within depot polymeric scaffolds. This strategy 
attempts to provide ingenious solutions to limitations of conventional liposomes such as 
short plasma half-lives, toxicity, stability, and poor control of cargo release over prolonged 
periods [144]. The lack of liposomal toxicity information in the pre-clinical stage is another 
issue that could hamper the success of these DDSs. Liposomal synthesis protocols must 
ensure the absence of impurities from organic solvents, free surfactants, and heavy metals, 
which could contribute to bias results. Because, toxic effects could arise from organic solvent 
residues, latest studies accentuate on liposomes formulations using organic solvents-free 
methods [145]. Although nanomedicine aims to prolong the half-life of the cargo incorpo-
rated in the DDS, some pharmacotherapies would need a chronic administration. In this 
sense, an exhaustive study of empty liposomes toxicity would help to exploit their best 
usage in different therapies.
10. Conclusions
Nanomedicine and especially liposomes represent a step forward to deliver diagnostic 
agents and/or therapeutic compounds in CNS diseases such as stroke, brain cancer, AD, 
PD, or epilepsy. Therefore, this manuscript outlines the most recent and relevant engi-
neered liposomal strategies to cirvumvent the BBB and its main efflux transporter, the P-gp. 
Moreover, important aspects to further optimize liposomal strategies are discussed at the 
end of this chapter.
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